Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Hongfang Wang, PhD, Sung Choe, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stéphane de Botton, MD PhD, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 541.

https://doi.org/10.1182/blood-2019-122703

Published: 2019

Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 545.

https://doi.org/10.1182/blood-2019-122671

Published: 2019

Journal Articles

Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms

Terra Lasho, PhD, Alexander Tischer, PhD, Guadalupe Belen Antelo, MD, Animesh Pardanani, MBBS, PhD, Christy Finke, BS, Giacomo Coltro, MD, Wilson I Gonsalves, MD, Ayalew Tefferi, MD, Abhishek A Mangaonkar, MBBS, Naseema Gangat, MBBS, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 1697.

https://doi.org/10.1182/blood-2019-128067

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Vijay Negi, PhD, Liat Goldberg, PhD, Yang Jo Chung, PhD, Masahiro Onozawa, MD, Peter D. Aplan, MD

Blood (2019) 134 (Supplement_1): 1346.

https://doi.org/10.1182/blood-2019-128675

Published: 2019

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Blood (2019) 134 (Supplement_1): 1416.

https://doi.org/10.1182/blood-2019-127082

Published: 2019

Journal Articles

A Distinct Metabolic Signature in DNMT3A-Mutated Leukemia

Yu-Jun Dai, PhD, Fang Hu, Si-Yuan He, Xiao-Peng Tian, Hong-Hong Li, Ze-Yuan Qin, Siliang Chen, Yang Liang, PhD

Blood (2019) 134 (Supplement_1): 1426.

https://doi.org/10.1182/blood-2019-121657

Published: 2019

Journal Articles

Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)

Jorge Cortes, MD, Mansour Alfayez, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, BSN, BA, Musa E. Yilmaz, MD, Nicholas J. Short, MD, Koji Sasaki, MD, Lucia Masarova, MD, Naveen Pemmaraju, MD, Gautam M. Borthakur, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc, Naval G. Daver, MD

Blood (2019) 134 (Supplement_1): 1447.

https://doi.org/10.1182/blood-2019-127257

Published: 2019

Journal Articles

The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium

Xiaofei He, B.S., Caleb Hawkins, B.S., Lauren Lawley, B.S., Mark Wunderlich, MS, Benjamin Mizukawa, Xiang-ming Zha, PhD, Stephanie Halene, MD, Jing Fang, MD PhD

Blood (2019) 134 (Supplement_1): 2661.

https://doi.org/10.1182/blood-2019-125455

Published: 2019

Journal Articles

Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Fatma Bulushi, Rahma Al-Riyami, MD, Zainab Al Hosni, MD, Bushra Al-Abri, Murtadha Al-Khabori, MD

Blood (2019) 134 (Supplement_1): 2604.

https://doi.org/10.1182/blood-2019-128402

Published: 2019

Journal Articles

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Maher Albitar, MD, Marina Y Konopleva, MD PhD, Ivan De Dios, BS, Jeffrey Justin Estella, BS, MS, Spiraggelos Antzoulatos, Steven M. Kornblau, MD, Antonio Cavazos, Sanam Loghavi, MD, Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc

Blood (2019) 134 (Supplement_1): 2730.

https://doi.org/10.1182/blood-2019-127383

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

R-2HG/KDM2B/RIPK1 Signaling Mediates Necroptosis in Myelodysplastic Syndromes

Shuanghong Zhu, Chen Mei, Hongyan Tong, Jie Jin, PhD

Blood (2019) 134 (Supplement_1): 5049.

https://doi.org/10.1182/blood-2019-125482

Published: 2019

Journal Articles

Comparison of Three Assays for Identification of IDH Mutations in AML

Sara Ribeiro, BSc, Dorte Wren, PhDFRCPath, Lisa Thompson, PhD MSc, FIBMS, Michael Hubank, PhD, David Taussig, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 5195.

https://doi.org/10.1182/blood-2019-126494

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

NARROW

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

A Distinct Metabolic Signature in DNMT3A-Mutated Leukemia

Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)

The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium

Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

R-2HG/KDM2B/RIPK1 Signaling Mediates Necroptosis in Myelodysplastic Syndromes

Comparison of Three Assays for Identification of IDH Mutations in AML

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only